Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Context Therapeutics Inc (CNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.19-7.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CNTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful commercialization of BioAtla antibody assets | Context Therapeutics secured exclusive rights to antibody assets via a BioAtla license amendment in May 2026. | Improving | no meaningful progress toward commercialization milestones by FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage biotechnology, not a business with established earnings: it is loss-making, recent financial performance is weak, and overall risk is high. The thesis is on watch, with low confidence, as clinical programs show some progress but legal and listing issues remain unresolved.
The evidence provides no valuation measure or clear account of market expectations, so whether CNTX is cheap, fair, or expensive versus peers is unclear. Its loss-making status and high risk are evident, but the expectations gap cannot be assessed from this snapshot.
Near-term results remain uncertain, with an elevated risk of an earnings miss; the evidence attributes this in part to CNTX's small size and its industry's high miss rate. Over the multi-year view, CTIM-76 development has reported interim safety and efficacy signals, while CT-202's planned trial timing is consistent with management's stated timeline. Legal challenges and the minimum-bid listing notice remain material execution risks.
The multi-year thesis depends on whether CTIM-76 and CT-202 can advance through clinical development and show meaningful progress. Near-term sector conditions are a secondary swing factor: strong results and guidance from healthcare bellwethers could sustain a sector tailwind, while weaker reports could remove it. Continued weakness in employment data could also add pressure to cyclical and healthcare names.
Over the next 1 to 3 years, CNTX's case rests on clinical progress, while weak financial performance, legal matters, and listing risk keep confidence low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Context Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -$0.43 in 2027 to less negative by FY28. |
| Broken |
| EPS loss worsens beyond -$0.43 in FY27 or fails to improve in FY28 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolution of stockholder litigation and Nasdaq listing compliance | A primary condition in Context Therapeutics Inc's published investment case. The stated target is complete resolution of litigation and maintain Nasdaq listing by end 2026. | Under Pressure | litigation escalates or Nasdaq delisting occurs in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.43 → $-0.43 · observed estimates
$0.00B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.43 | $0 | 7 / 8 |
| 2026-07-25 | $-0.43 | $0 | 7 / 8 |
| 2026-07-26 | $-0.43 | $0 | 7 / 8 |
| 2026-07-27 | $-0.43 | $0 | 7 / 8 |
| 2026-07-28 | $-0.43 | $0 | 7 / 8 |
| 2026-07-29 | $-0.43 | Unavailable | 6 / 0 |
| 2026-07-30 | $-0.43 | $0 | 7 / 8 |
| 2026-07-31 | $-0.43 | $0 | 7 / 8 |
| 2026-08-01 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-02 | $-0.43 | $0 | 7 / 8 |
| 2026-08-03 | $-0.43 | $0 | 7 / 8 |
| 2026-08-04 | $-0.43 | $0 | 7 / 8 |
| 2026-08-05 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-06 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-07 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-08 | $-0.45 | $0 | 7 / 8 |
| 2026-08-09 | $-0.45 | $0 | 7 / 8 |
| 2026-08-10 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-11 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-12 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-13 | $-0.41 | $0 | 7 / 8 |
| 2026-08-14 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-15 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-16 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-17 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-18 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-19 | $-0.40 | Unavailable | 6 / 0 |
| 2026-08-20 | $-0.41 | Unavailable | 6 / 0 |
| 2026-08-21 | $-0.41 | Unavailable | 6 / 0 |
| 2026-08-22 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-23 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-24 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-25 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-26 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-27 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-28 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-29 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-30 | $-0.43 | Unavailable | 6 / 0 |
| 2026-08-31 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-01 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-02 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-03 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-04 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-05 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-06 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-07 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-08 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-09 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-10 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-11 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-12 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-13 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-14 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-15 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-16 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-17 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-18 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-19 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-20 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-21 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-22 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-23 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-24 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-25 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-26 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-27 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-28 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-29 | $-0.43 | Unavailable | 6 / 0 |
| 2026-09-30 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-01 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-02 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-03 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-04 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-05 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-06 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-07 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-08 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-09 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-10 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-11 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-12 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-13 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-14 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-15 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-16 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-17 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-18 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-19 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-20 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-21 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-22 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-23 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-24 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-25 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-26 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-27 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-28 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-29 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-30 | $-0.43 | Unavailable | 6 / 0 |
| 2026-10-31 | $-0.43 | Unavailable | 6 / 0 |
| 2026-11-01 | $-0.43 | Unavailable | 6 / 0 |
| 2026-11-02 | $-0.43 | Unavailable | 6 / 0 |
| 2026-11-03 | $-0.43 | Unavailable | 6 / 0 |
| 2026-11-04 | $-0.43 | Unavailable | 6 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.